PRM7 Antibody

What is PRMT7 and what are its primary functions in cellular processes?

PRMT7 belongs to the protein arginine methyltransferase family and primarily catalyzes monomethylation of arginine residues in target proteins. It plays crucial roles in various cellular processes including gene expression regulation, protein signaling, and post-translational modifications. PRMT7 is known to participate in epigenetic regulation through protein methylation, making it a key player in cell biology research, particularly in cancer biology and developmental biology. PRMT7 is localized to both the nucleus and cytoplasm, with moderate expression observed in adult brain and lung tissues .

The enzyme contains two methyltransferase domains, each with a putative S-adenosylmethionine (AdoMet) binding motif. The N-terminal methyltransferase domain closely resembles the catalytic core of PRMT5, while the C-terminal domain is most similar to that of PRMT1. Database analysis has identified three splice variants of PRMT7 .

What applications are PRMT7 antibodies commonly used for in research settings?

PRMT7 antibodies serve as valuable tools for multiple research applications, including:

• Western blotting (WB): For detecting PRMT7 protein expression levels in various cell and tissue lysates

• Immunoprecipitation (IP): To isolate PRMT7 and its interacting proteins

• Immunofluorescence (IF): For studying subcellular localization of PRMT7

• Flow cytometry: For analyzing PRMT7 expression in individual cells within populations

These antibodies allow researchers to gain insights into PRMT7 expression levels, subcellular localization, and potential interactions with other proteins. This information is crucial for understanding the mechanisms underlying PRMT7-mediated processes and for identifying potential therapeutic targets for diseases associated with dysregulated protein methylation .

How is PRMT7 involved in antiviral immune responses?

PRMT7 plays a significant regulatory role in antiviral immunity, particularly in the RIG-I-MAVS signaling pathway. Research has demonstrated that PRMT7 directly interacts with and monomethylates MAVS (Mitochondrial Antiviral Signaling protein) at arginine 232 (R232). This methylation disrupts the binding between RIG-I and MAVS, thereby inhibiting MAVS aggregation and type I interferon signaling pathway activation .

During RNA virus infection, PRMT7 is downregulated and dissociates from MAVS, leading to decreased R232 monomethylation and increased RIG-I/MAVS interaction. This results in subsequent MAVS aggregation and type I interferon signaling activation, enhancing the antiviral immune response .

Analysis of expression data from several GEO databases has revealed that PRMT7 is significantly downregulated in blood samples from SARS-CoV-2 and Ebola virus (EBoV)-infected patients, as well as in H1N1-infected bronchial epithelial cells, further supporting its role in antiviral immunity .

How does PRMT7 influence cancer immunotherapy and tumor growth?

PRMT7 has emerged as a significant factor in cancer immunotherapy. Research has demonstrated that PRMT7 deficiency enhances sensitivity to immune checkpoint inhibitor (ICI) therapy. In a CRISPR/Cas9 genetic screen using the B16.F10 murine melanoma model, PRMT7 ranked as a top hit among genes that, when deleted, improved anti-tumor responses to immunotherapy .

PRMT7 deficiency or inhibition in B16.F10 melanoma results in:

• Increased expression of genes in the interferon pathway, antigen presentation, and chemokine signaling

• Reduced expression of DNA methyltransferases (DNMTs)

• Loss of DNA methylation in regulatory regions of endogenous retroviral elements (ERVs)

• Increased expression of ERVs

• Increased expression of RIG-I and MDA5 with reduced repressive histone marks (H4R3me2s) at their promoters

Tumors with PRMT7 deficiency showed enhanced T cell infiltration and decreased presence of myeloid-derived suppressor cells (MDSCs), which are known to mediate resistance to ICI therapy. This suggests that PRMT7 functions as an epigenetic checkpoint for RIG-I, MDA5, and their ERV-dsRNA ligands, facilitating immune escape .

What methodological approaches can be used to study PRMT7-mediated methylation events?

Studying PRMT7-mediated methylation requires a multi-faceted approach:

• Site-directed mutagenesis: Generating point mutations (e.g., R232K or R232F) in potential PRMT7 substrates. R to K mutations prevent methylation at the site, while R to F mutations can mimic methylated arginine .

• Mass spectrometry analysis: High-resolution mass spectrometry of enriched peptides from anti-mono-methyl-arginine antibodies can identify PRMT7 methylation targets. This approach has been successfully used to establish the PRMT7 methylome .

• Knock-in mouse models: Generation of models with mutations at specific methylation sites (e.g., MAVS R232K-KI mice) allows for in vivo assessment of methylation effects on immune responses and survival during viral infections .

• Peptide inhibitors: Designing peptide inhibitors that disrupt PRMT7-substrate interactions (e.g., PiPRMT7-MAVS) can be used to probe the functional consequences of blocking PRMT7-mediated methylation .

• Specific PRMT7 inhibitors: Chemical inhibitors like SGC3027 can be used to pharmacologically inhibit PRMT7 activity and study the resulting effects on target pathways .

How do researchers differentiate between PRMT7 and other PRMT family members?

Differentiating between PRMT7 and other PRMT family members requires careful consideration of several factors:

• Antibody specificity: Using monoclonal antibodies with validated specificity for PRMT7, such as those targeting unique epitopes within PRMT7's sequence. The monoclonal antibody PCRP-PRMT7-1A4 has been validated for specificity against PRMT7 .

• Methylation patterns: PRMT7 primarily catalyzes monomethylation of arginine residues, whereas other PRMTs can catalyze asymmetric or symmetric dimethylation. Using antibodies specific to different methylation states can help distinguish PRMT7 activity .

• Substrate specificity: PRMT7 has distinct substrate preferences compared to other PRMTs. For example, its monomethylation of MAVS at R232 is a specific interaction that can be used to distinguish PRMT7 activity .

• Molecular weight verification: PRMT7 has a calculated molecular weight of approximately 78 kDa, which can be used to distinguish it from other PRMT family members in western blot analyses .

What controls should be included when using PRMT7 antibodies for research applications?

When designing experiments using PRMT7 antibodies, the following controls should be included:

• Positive controls: Lysates from cells known to express PRMT7, such as HeLa, SW620, MCF7, NIH/3T3, mouse testis, mouse brain, rat testis, and rat brain tissues have been validated for PRMT7 expression .

• Negative controls:

  • PRMT7 knockout or knockdown cells/tissues

  • Isotype control antibodies to assess non-specific binding

  • Secondary antibody-only controls to evaluate background signal

• Peptide competition assays: Pre-incubation of the PRMT7 antibody with the immunizing peptide should abolish specific signals.

• Cross-reactivity tests: If working across species, validate the antibody's reactivity with the target species. Current PRMT7 antibodies have been validated for human, mouse, and rat samples .

• Loading controls: Include appropriate loading controls (e.g., β-actin, GAPDH) for western blot experiments to ensure equal protein loading across samples.

How can PRMT7 antibodies be used to investigate gene regulation and signaling pathways?

PRMT7 antibodies can be powerful tools for investigating gene regulation and signaling pathways through several approaches:

• Chromatin Immunoprecipitation (ChIP): To identify genomic regions where PRMT7 may directly influence gene expression through histone modification.

• Co-Immunoprecipitation (Co-IP): To identify protein-protein interactions between PRMT7 and components of signaling pathways. This approach has successfully identified interactions between PRMT7 and MAVS .

• Immunoblotting following pathway stimulation: To assess changes in PRMT7 expression or localization following activation of specific signaling pathways, such as during viral infection .

• Combination with transcriptome analysis: Using PRMT7 antibodies for immunoprecipitation followed by RNA-seq to identify PRMT7-associated RNAs.

• Pathway analysis following PRMT7 modulation: Using antibodies to detect changes in signaling pathway components (e.g., phosphorylation of TBK1 and IRF3) following PRMT7 knockout, knockdown, or inhibition .

These approaches have revealed that PRMT7 negatively regulates the IFN-γ pathway, antigen presentation, and chemokine signaling. PRMT7 deficiency leads to enrichment of genes related to these pathways and elevation of interferon signaling response genes such as Trim25, Oas2, Trim21, Stat1, Nlrc5, Irf7, and Oas3 .

What approaches can optimize PRMT7 antibody performance in immunofluorescence studies?

To optimize PRMT7 antibody performance in immunofluorescence studies, researchers should consider:

• Fixation optimization:

  • Test different fixation methods (4% paraformaldehyde, methanol, or combination)

  • Optimize fixation duration to preserve epitope accessibility while maintaining cellular morphology

• Permeabilization conditions:

  • Since PRMT7 localizes to both cytoplasm and nucleus, ensure adequate permeabilization with appropriate detergents (e.g., 0.1-0.5% Triton X-100 or 0.1-0.3% Saponin)

  • Adjust permeabilization time to balance antibody access with preservation of cellular structures

• Antigen retrieval:

  • Consider heat-induced or enzymatic antigen retrieval methods if initial results show weak signals

  • Test different buffer compositions (citrate, EDTA, or Tris-based)

• Blocking optimization:

  • Use appropriate blocking agents (BSA, normal serum, commercial blocking solutions)

  • Extend blocking time (1-2 hours) to reduce background staining

• Antibody dilution and incubation:

  • Test a range of antibody dilutions around the manufacturer's recommended 1-2 μg/ml

  • Optimize incubation time and temperature (overnight at 4°C often yields best results)

• Signal amplification:

  • Consider tyramide signal amplification for low abundance targets

  • Use highly cross-adsorbed secondary antibodies to minimize background

• Counterstaining:

  • Include nuclear stains (DAPI, Hoechst) to provide structural context

  • Consider co-staining with organelle markers to confirm subcellular localization

How should researchers interpret changes in PRMT7 expression in disease states?

When interpreting changes in PRMT7 expression in disease states, researchers should consider:

• Context-dependent regulation: PRMT7 expression changes should be interpreted in the specific disease context. For example, PRMT7 is downregulated in viral infections like SARS-CoV-2 and Ebola virus, which appears to be part of the host antiviral response .

• Correlation with clinical outcomes: In cancer, elevated PRMT7 mRNA expression has been associated with reduced patient survival in melanoma, suggesting a potential role in tumor progression or therapy resistance .

• Pathway integration: Changes in PRMT7 expression should be analyzed in conjunction with alterations in related pathways:

  • Interferon signaling pathways

  • Antigen presentation machinery

  • Chemokine signaling

  • DNA methylation patterns and endogenous retroviral element expression

• Cell type specificity: The significance of PRMT7 expression changes may vary between cell types. For example, PRMT7 deficiency in tumor cells enhances T cell infiltration and decreases immunosuppressive myeloid cells .

• Temporal dynamics: Consider the timing of PRMT7 expression changes relative to disease progression. During RNA virus infection, PRMT7 downregulation appears to be part of the host response mechanism .

• Therapeutic implications: Changes in PRMT7 expression may predict responsiveness to certain therapies. PRMT7 deficiency enhances sensitivity to immune checkpoint inhibitor therapy in melanoma .

What methodological considerations are important when quantifying PRMT7-mediated methylation?

Quantifying PRMT7-mediated methylation requires careful attention to several methodological considerations:

• Antibody specificity for methylation states:

  • Use antibodies specific for monomethylated arginine (Rme1) rather than di-methylated forms

  • Validate antibody specificity using synthetic peptides with defined methylation states

• Site-specific detection methods:

  • For known methylation sites like MAVS R232, use site-specific methylation antibodies

  • Consider generating custom antibodies against known PRMT7 methylation sites

• Mass spectrometry approaches:

  • Use SILAC (Stable Isotope Labeling by Amino acids in Cell culture) combined with methyl-arginine enrichment

  • Apply high-resolution mass spectrometry to detect and quantify methylated peptides

  • Compare samples from control and PRMT7-knockdown cells to identify PRMT7-specific methylation events

• Controls for specificity:

  • Include samples from PRMT7-knockout or knockdown systems

  • Use methylation-deficient mutants (e.g., R232K) as negative controls

  • Include PRMT7-specific inhibitor treatments as additional controls

• Normalization strategies:

  • Normalize methylation signals to total protein levels

  • Consider using unmethylated peptide standards for absolute quantification

  • Account for variations in immunoprecipitation efficiency across samples

How can researchers distinguish between direct and indirect effects of PRMT7 inhibition?

Distinguishing between direct and indirect effects of PRMT7 inhibition requires a multi-faceted approach:

• Substrate identification and validation:

  • Use proteomics approaches to identify direct PRMT7 substrates

  • Validate candidate substrates using in vitro methylation assays with purified PRMT7

  • Confirm direct interactions through co-immunoprecipitation and proximity ligation assays

• Temporal analysis:

  • Monitor changes following PRMT7 inhibition over time to distinguish early (likely direct) effects from late (potentially indirect) effects

  • Use pulse-chase experiments to track the kinetics of methylation changes

• Rescue experiments:

  • Reintroduce wild-type PRMT7 to PRMT7-deficient systems to rescue direct effects

  • Use catalytically inactive PRMT7 mutants to distinguish between enzymatic and scaffolding functions

• Combinatorial approaches:

  • Compare effects of PRMT7 genetic knockout/knockdown with specific inhibitors

  • Combine PRMT7 inhibition with inhibition of downstream effectors to map pathway dependencies

• Substrate mutation studies:

  • Generate methylation-deficient mutants of suspected PRMT7 substrates (e.g., MAVS R232K)

  • Compare phenotypes between PRMT7 inhibition and substrate mutation

  • Epistasis experiments can help position PRMT7 within signaling cascades

• Pathway analysis:

  • Use transcriptomic and proteomic approaches to identify pathways affected by PRMT7 inhibition

  • Cross-reference with known PRMT7 substrates to distinguish direct from indirect effects

What are the emerging applications of PRMT7 antibodies in therapeutic development?

PRMT7 antibodies are becoming increasingly valuable in therapeutic development through several emerging applications:

• Target validation for drug development:

  • PRMT7 antibodies can help validate PRMT7 as a therapeutic target in diseases like cancer

  • They allow researchers to confirm target engagement of PRMT7 inhibitors in preclinical studies

• Biomarker development:

  • PRMT7 expression analysis using antibodies may serve as a predictive biomarker for immune checkpoint inhibitor therapy response

  • Assessment of PRMT7 substrates' methylation status could indicate PRMT7 activity in patient samples

• Mechanism-of-action studies:

  • Antibodies targeting PRMT7 and its methylation sites help elucidate how PRMT7 inhibitors exert their effects

  • They can reveal how PRMT7 inhibition modulates immune responses in combination therapies

• Combination therapy design:

  • Research using PRMT7 antibodies has shown that PRMT7 inhibition enhances response to immune checkpoint inhibitors, suggesting potential for combination approaches

  • This allows rational design of combination therapies targeting both PRMT7 and immune checkpoints

• Novel inhibitor development:

  • Peptide inhibitors that disrupt PRMT7-substrate interactions (like PiPRMT7-MAVS) have shown promise in enhancing antiviral responses

  • Structural studies using PRMT7 antibodies can guide the development of more specific small molecule inhibitors

How might PRMT7 antibodies contribute to understanding post-translational regulation in complex diseases?

PRMT7 antibodies offer significant potential for advancing our understanding of post-translational regulation in complex diseases:

• Methylation landscapes in disease progression:

  • PRMT7 antibodies enable mapping of arginine monomethylation patterns across disease stages

  • Changes in PRMT7-mediated methylation can be correlated with disease severity and outcomes

• Integration with other post-translational modifications:

  • Co-detection of PRMT7-mediated methylation with other modifications (phosphorylation, ubiquitination) can reveal crosstalk between different regulatory mechanisms

  • This approach helps construct more comprehensive models of protein regulation in disease

• Single-cell analysis of PRMT7 activity:

  • Combining PRMT7 antibodies with single-cell technologies can reveal cell-type-specific roles in heterogeneous diseases

  • This may identify specific cellular populations where PRMT7 inhibition would be most beneficial

• Tissue-specific regulation:

  • PRMT7 antibodies facilitate analysis of tissue-specific methylation patterns in complex diseases

  • This helps identify tissue-specific vulnerabilities that could be therapeutically targeted

• Dynamic regulation during disease development:

  • Time-course studies using PRMT7 antibodies can reveal how methylation patterns change during disease progression

  • This temporal information can identify optimal intervention points for PRMT7-targeted therapies

The integration of PRMT7 antibody-based research with multi-omics approaches will continue to deepen our understanding of how this methyltransferase contributes to disease pathogenesis and potential therapeutic interventions.